Daily Respiratory Research Analysis
Analyzed 129 papers and selected 3 impactful papers.
Summary
Three impactful respiratory studies stood out today. A randomized phase 2 trial (FLOWERS) shows that adding savolitinib to first-line osimertinib markedly increases response rates in EGFR-mutant, MET-aberrant NSCLC. An interpretable model predicts infants’ age at first RSV infection from birth timing and surveillance data, while an IPD meta-analysis confirms high-flow nasal cannula reduces desaturation during bronchoscopy, with ≥45 L/min flows performing best.
Research Themes
- Precision oncology in lung cancer (EGFR/MET co-targeting)
- Predictive epidemiology for infant RSV infection timing
- Periprocedural oxygenation optimization during bronchoscopy
Selected Articles
1. Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).
In treatment-naïve EGFR-mutant NSCLC with de novo MET aberrations, adding savolitinib to first-line osimertinib markedly increased ORR (90.5% vs 60.9%) and disease control, albeit with more grade ≥3 adverse events (57.1% vs 8.7%). These data support dual EGFR/MET inhibition as a promising strategy in this molecularly defined subgroup.
Impact: Demonstrates substantial efficacy gains from co-targeting MET with EGFR in first-line therapy, addressing a known resistance pathway and potentially reshaping management for MET-aberrant EGFR-mutant NSCLC.
Clinical Implications: Consider comprehensive MET assessment (amplification/overexpression) at baseline in EGFR-mutant NSCLC and, if confirmed in phase 3, integrate osimertinib–savolitinib combinations for eligible patients with careful toxicity monitoring.
Key Findings
- Confirmed ORR improved from 60.9% (osimertinib) to 90.5% (osimertinib+savolitinib).
- Disease control rate increased to 95.2% with combination versus 87% with monotherapy.
- Grade ≥3 treatment-related adverse events were more frequent with combination (57.1% vs 8.7%).
Methodological Strengths
- Randomized, multicenter trial with predefined molecular selection (de novo MET aberrations and EGFR mutations).
- Clinically meaningful, objective primary endpoint (confirmed ORR) with confidence intervals.
Limitations
- Small sample size (n=44) and open-label design may limit generalizability.
- Short-term response endpoints; mature PFS/OS data not reported.
Future Directions: Conduct adequately powered, blinded phase 3 trials with PFS/OS endpoints; refine biomarkers (MET amplification thresholds, IHC quantification) to optimize patient selection and manage toxicity.
To investigate the efficacy and safety of osimertinib plus savolitinib for patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations and de novo MET aberrations, we conducted a randomized, multicenter, open-label, phase 2 study (ClinicalTrials.gov identifier: NCT05163249). Treatment-naïve patients with locally advanced or metastatic NSCLC harboring de novo MET amplification or overexpression and EGFR mutations were randomized to receive osimertinib monotherapy (cohort 1, 80 mg orally once daily) or combination therapy (cohort 2, osimertinib 80 mg orally once daily and savolitinib 300 mg orally twice daily). The primary endpoint was the confirmed objective response rate (ORR). A total of 44 patients were randomized to either cohort 1 (n = 23) or cohort 2 (n = 21). The pre-specified study endpoint was achieved. The confirmed ORR was 60.9% (95% confidence interval [CI]: 38.5-80.3) in cohort 1 and 90.5% (95% CI: 69.6-98.8) in cohort 2, with disease control rates of 87% (95% CI: 66.4-97.2) and 95.2% (95% CI: 76.2-99.9). Treatment-related adverse events of grade 3 or higher occurred in 2 patients (8.7%) in cohort 1 and 12 patients (57.1%) in cohort 2. Osimertinib plus savolitinib showed promising antitumor activity and manageable safety.
2. Predicting age of respiratory syncytial virus infection from birth timing.
An interpretable probability model using birthdate, demographics, and public RSV circulation data explained ~37% of variance in infant age at first RSV infection and generalized across four U.S. datasets, accurately predicting timing in two cohorts. This approach enables scalable risk stratification without costly active surveillance.
Impact: Provides a practical, generalizable tool to estimate infant RSV infection timing, informing optimal deployment of maternal vaccines and monoclonal antibodies and enabling targeted prevention in critical susceptibility windows.
Clinical Implications: Health systems can leverage routinely available surveillance and birth data to anticipate infection timing, refine schedules for maternal RSV vaccination and nirsevimab, and prioritize outreach to infants predicted to be infected early.
Key Findings
- Model explained nearly 37% of variance in age at first RSV infection.
- Generalized across four independent U.S. datasets and accurately predicted timing in two cohorts.
- Inputs required only birthdate, demographic covariates, and publicly available RSV circulation data.
Methodological Strengths
- Multi-cohort external validation with consistent performance.
- Interpretable framework using publicly available surveillance data enhances scalability.
Limitations
- Predominantly U.S.-based datasets; generalizability to other regions requires testing.
- Focus on first year of life; does not address reinfections or post-first-year dynamics.
Future Directions: Adapt and validate the model in diverse geographies and healthcare settings; integrate immunization uptake and effectiveness to optimize population-level RSV prevention strategies.
Respiratory syncytial virus (RSV) infects nearly all children by age 2 to 3 years, and early-life infection-defined using active and passive surveillance with quantitative polymerase chain reaction- and serology-identified infection-has been implicated as a causal factor in childhood asthma. As such, identifying infants that are likely to be infected with RSV during this critical susceptibility window has important implications for identifying individuals at risk for chronic respiratory sequelae. However, determining the age of RSV infection in large populations is challenging because many infections are asymptomatic, making accurate detection dependent on intensive and costly surveillance. To address this, we developed a probability model for age of first RSV infection. It uses an infant's birthdate, demographic covariates, and publicly available RSV circulation data to determine the probability they were first infected at any age from birth to one year. Our model is interpretable, accounts for nearly 37% of the variance in age at first infection, and generalizes across four independent datasets collected from participants in the United States, where we use it to accurately predict age of first infection in two independent cohorts. Our work facilitates reliable estimation of the age of infant RSV infection during the first year of life without the need for active surveillance.
3. High flow nasal cannula versus conventional oxygen therapy during bronchoscopy: A systematic review and individual participant data meta-analysis.
Across 17 RCTs (n=3,116), HFNC reduced desaturation (OR 0.23), procedure interruptions, escalation of respiratory support, and airway interventions during bronchoscopy compared with COT. IPD analyses (n=1,344) identified greater benefits at lower BMI and baseline respiratory/heart rates, and flows ≥45 L/min further decreased hypoxemia risk.
Impact: Provides high-level evidence to standardize oxygenation strategies during bronchoscopy and offers actionable guidance on patient selection and optimal HFNC flow settings.
Clinical Implications: Adopt HFNC as default oxygenation during adult bronchoscopy, target flows ≥45 L/min when feasible, and anticipate larger benefits in patients with lower BMI and lower baseline respiratory/heart rates.
Key Findings
- HFNC reduced desaturation during bronchoscopy versus COT (OR 0.23, 95% CI 0.15–0.34).
- Procedure interruptions, escalation of respiratory support, and airway interventions were all significantly lower with HFNC.
- Flows ≥45 L/min and lower baseline BMI/respiratory/heart rates were associated with greater benefit in IPD analyses.
Methodological Strengths
- Systematic review of RCTs with pre-registered protocol and large aggregate sample.
- Individual participant data analyses enabling exploration of treatment-effect modifiers and optimal flow settings.
Limitations
- IPD available for only 6 of 17 RCTs; potential selection bias.
- Heterogeneity in bronchoscopy types, sedation practices, and HFNC parameters across trials.
Future Directions: Prospective trials in higher-risk populations (e.g., severe hypoxemia, obesity), standardized HFNC protocols, and cost-effectiveness analyses to inform guideline recommendations.
BACKGROUND: High-flow nasal cannula (HFNC) is superior to conventional oxygen therapy (COT) in preventing hypoxaemia during bronchoscopy. However, factors associated with HFNC effectiveness remain unclear. We performed an individual participant data meta-analysis (IPD-MA) to identify treatment modifiers for HFNC during bronchoscopy. METHODS: We systematically reviewed randomised controlled trials (RCTs) comparing HFNC and COT during bronchoscopy in adults (January 2000-September 2025) and requested IPD from corresponding investigators. The primary outcome was desaturation during bronchoscopy. Conventional meta-analysis was performed using random-effect model; one-stage regression model was used for IPD-MA. Results were reported as odds ratios (ORs) or mean difference and 95% confidence intervals (CIs). RESULTS: Seventeen RCTs (3,116 patients: 1680 HFNC, 1436 COT) were included. Compared to COT, HFNC significantly reduced desaturation (OR 0.23, 95% CI 0.15-0.34), procedure interruption (OR 0.36, 95% CI 0.20-0.67), respiratory support escalation (OR 0.25, 95% CI 0.11-0.55), and airway intervention (OR 0.19, 95% CI 0.10-0.36) during bronchoscopy. IPD was obtained from six RCTs (1,344 patients). Significant interactions were observed between treatment effect and body mass index, baseline respiratory and heart rates, with greater relative benefit at lower values. HFNC flows ≥45 L/min were associated with reduced desaturation risk (OR 0.28, 95% CI 0.12-0.65). CONCLUSIONS: HFNC is superior to COT in reducing desaturation and procedure-related interruptions during bronchoscopy. Exploratory analyses suggest greater relative benefits in patients with lower body mass index and lower baseline respiratory and heart rates. HFNC flows ≥45 L/min furtherreduce desaturation risk. Further studies are needed in higher-risk patients. TRIAL REGISTRATION: International Prospective Register of Systematic Reviews; No.:CRD420251008924; URL: https://www.crd.york.ac.uk/prospero/.